Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yufeng Ningxin Drip Pill post-marketing re-evaluation in stable coronary artery disease after coronary revascularization
ChiCTR1900023589Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of yufeng ningxin in coronary arteriosclerosis (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: peak VO2 percent predicted. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
yufeng ningxin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900023589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023589.